Annexon, Inc. ANNX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-7.93
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$206.7M | — | -$186.5M | $211.6M |
| 2024 | — | -$138.2M | — | -$118.0M | $293.1M |
| 2023 | — | -$134.2M | — | -$121.3M | $250.6M |
| 2022 | — | -$141.9M | — | -$122.8M | $231.2M |
| 2021 | — | -$130.3M | — | -$107.8M | $231.9M |
| 2020 | — | -$63.4M | — | -$53.6M | $344.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 2026-06-11 | Option exercise | 30,646 | $1.85 |
| Satter Muneer A | director | 2026-05-28 | Buy | 613,497 | $5.41 |
| Carson William H. | director | 2026-05-11 | Buy | 8,000 | $5.78 |
| Carson William H. | director | 2026-04-10 | Buy | 8,000 | $6.20 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.93 (distress)
- Working capital / assets 0.719
- Retained earnings / assets -3.305
- EBIT / assets -0.78
- Equity / liabilities 3.211
Source: SEC EDGAR filings · CIK 0001528115 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.